We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.
- Authors
Alberts, Steven R; Sargent, Daniel J; Nair, Suresh; Mahoney, Michelle R; Mooney, Margaret; Thibodeau, Stephen N; Smyrk, Thomas C; Sinicrope, Frank A; Chan, Emily; Gill, Sharlene; Kahlenberg, Morton S; Shields, Anthony F; Quesenberry, James T; Webb, Thomas A; Farr, Gist H, Jr; Pockaj, Barbara A; Grothey, Axel; Goldberg, Richard M
- Abstract
Leucovorin, fluorouracil, and oxaliplatin (FOLFOX) is the standard adjuvant therapy for resected stage III colon cancer. Adding cetuximab to FOLFOX benefits patients with metastatic wild-type KRAS but not mutated KRAS colon cancer.
- Publication
JAMA, 2012, Vol 307, Issue 13, p1383
- ISSN
1538-3598
- Publication type
Journal Article
- DOI
10.1001/jama.2012.385